Literature DB >> 22644344

Bevacizumab treatment in hereditary hemorrhagic teleangiectasia.

Sebastian Föllner, Michael Ibe, Jens Schreiber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22644344     DOI： 10.1007/s00228-012-1308-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

1.  Bevacizumab in hereditary hemorrhagic telangiectasia.

Authors:  Prithviraj Bose; Jennifer L Holter; George B Selby
Journal:  N Engl J Med       Date:  2009-05-14       Impact factor: 91.245

2.  Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution.

Authors:  Elisabetta Buscarini; Guido Manfredi; Alessandro Zambelli
Journal:  Liver Transpl       Date:  2008-11       Impact factor: 5.799

3.  Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

Authors:  Dimitri Flieger; Sabine Hainke; Wolfgang Fischbach
Journal:  Ann Hematol       Date:  2006-06-29       Impact factor: 3.673

4.  Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.

Authors:  Solène Taugourdeau-Raymond; F Rouby; A Default; M-J Jean-Pastor
Journal:  Eur J Clin Pharmacol       Date:  2012-02-16       Impact factor: 2.953

5.  Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.

Authors:  Anna Cirulli; Arcangelo Liso; Francesco D'Ovidio; Anna Mestice; Giovanna Pasculli; Mauro Gallitelli; Rita Rizzi; Giorgina Specchia; Carlo Sabbà
Journal:  Acta Haematol       Date:  2003       Impact factor: 2.195

6.  Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.

Authors:  Andrew Mitchell; Leon A Adams; Gerry MacQuillan; Jon Tibballs; Rohan vanden Driesen; Luc Delriviere
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

7.  Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.

Authors:  Paola Giordano; Gennaro M Lenato; Paola Pierucci; Patrizia Suppressa; Maria Altomare; Giancarlo Del Vecchio; Giovanna Di Bitonto; Domenico De Mattia; Ginevra Guanti; Carlo Sabbà
Journal:  J Pediatr Hematol Oncol       Date:  2009-08       Impact factor: 1.289

8.  The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.

Authors:  Jana Simonds; Frank Miller; Jess Mandel; Terence M Davidson
Journal:  Laryngoscope       Date:  2009-05       Impact factor: 3.325
  8 in total
  1 in total

Review 1.  Future treatments for hereditary hemorrhagic telangiectasia.

Authors:  Florian Robert; Agnès Desroches-Castan; Sabine Bailly; Sophie Dupuis-Girod; Jean-Jacques Feige
Journal:  Orphanet J Rare Dis       Date:  2020-01-07       Impact factor: 4.123
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.